EIDD

Many drug candidates fail in development due to unacceptable toxicology profiles. The EIDD is unique among academic institutions and has established capabilities and protocols to assess active compounds at very early stages of the development process to quickly eliminate those with toxicity and genotoxicity concerns that could threaten their ability to advance into clinical testing. This data also provides structural insights that are critical to the design of drug candidates that minimize adverse side-effects... Founded in 2008, the EIDD was constructed to complement the substantial track record of antiviral research at Emory University with the tools, expertise, and capabilities necessary to optimize and advance new generations of active leads through pre-clinical development and IND submission... The EIDD was created to provide organization, facilities and resources to translate academic drug discovery into clinical candidates. In addition to performing lead drug discovery, lead..

Also known as: Emory Institute for Drug Development

Primary location: Atlanta United States